Overview

A Study of AK0529 in Adults Patients Hospitalized With RSV Infection

Status:
COMPLETED
Trial end date:
2024-06-28
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multicenter, phase II study to be conducted in adults hospitalized with RSV infection in China. The main objectives of this study are to investigate the safety, pharmacokinetics and efficacy of AK0529 in adult RSV patients.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Ark Biopharmaceutical Co., Ltd.
Treatments:
ziresovir